Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).

Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).

Jackson, V ; Silva, S ; Abbattista, M ; Guise, Christopher ; Bull, M ; Ashoorzadeh, A ; Hart, C ; Pearce, T ; Smaill, Jeffrey ; Patterson, Adam
Identifier: http://hdl.handle.net/2292/27742
Issue Date: 2015
Reference: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2015
Rights (URI): https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm

Show full item record

Files in this item

Icon
Related URL: http://www.aacr.org/Documents/Targets15_AbstractsPosterA.pdf
Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics